Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:MTVA

MetaVia Q1 2025 Earnings Results & Report

MetaVia logo
$1.36 -0.07 (-4.90%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$1.33 -0.03 (-2.21%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MetaVia beat analyst earnings expectations in its Q1 2025 results, released May 14, 2025. The company reported EPS of -$3.96 versus the -$6.27 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
12:00 AM ET

MetaVia EPS Results

Actual EPS
-$3.96
Consensus EPS
-$6.27
Beat/Miss
Beat by +$2.31
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 5 quarters

MetaVia Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

MetaVia's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

MetaVia's Q1 2025 Press ReleasePress Release
(8-K)
MetaVia's Q1 2025 Quarterly reportQuarterly report
(10-Q)

MetaVia Q1 2025 Earnings FAQ

MetaVia (NASDAQ:MTVA) reported earnings of -$3.96 per share for Q1 2025, beating the consensus estimate of -$6.27. The report was announced on Wednesday, May 14, 2025.

MetaVia's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for MetaVia on the company's earnings history page.

MetaVia Earnings Headlines

MetaVia Appoints Sarah Browne As CMO
October 13 at 1:34 PM  |  rttnews.comhttps://www.rttnews.com/3698548/metavia-appoints-sarah-browne-as-cmo.aspx
Metavia Inc. Announces Appointment of Sarah Browne, M.D. as Chief Medical Officer, Effective October 12, 2026
October 13 at 1:34 PM  |  marketscreener.comM
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 15 at 1:00 AM  |  Chaikin Analytics (Ad)
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
October 13 at 8:31 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/metavia-appoints-seasoned-clinical-development-executive-sarah-browne-md-as-chief-medical-officer-302905979.html
MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction
September 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/mtva-preclinical-findings-support-da-122500251.html
MetaVia Inc.: MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
September 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69533768-metavia-inc-metavia-announces-preclinical-findings-supporting-biological-rationale-for-da-1726-s-waist-circumference-reduction-008.htm
See More MetaVia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MetaVia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MetaVia and other key companies, straight to your email.

About MetaVia

MetaVia (NASDAQ:MTVA), Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s programs are designed to address conditions including excess weight, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease associated with metabolic dysfunction.

MetaVia’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed as a potential treatment for obesity and related metabolic complications. The company is also developing DA-1241, an oral investigational GPR119 agonist intended for the treatment of MASH and type 2 diabetes. These candidates are in clinical development and have not been approved for commercial use.

The company was formerly known as NeuroBo Pharmaceuticals, Inc. and adopted the MetaVia name as part of its strategic focus on metabolic disease. MetaVia’s development programs are based in part on technology licensed from Dong-A Socio Holdings and its affiliates. The company is headquartered in the United States and conducts clinical development activities in collaboration with international partners.

View MetaVia Profile
Earnings Tools